Roche's giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer

Core Insights - Roche announced positive results from the phase III lidERA Breast Cancer study, demonstrating that giredestrant significantly reduces the risk of invasive disease recurrence or death by 30% compared to standard-of-care endocrine therapy [1][2][5] Group 1: Study Results - At the three-year mark, 92.4% of patients treated with giredestrant were alive and free of invasive disease, compared to 89.6% in the standard-of-care endocrine therapy group [2][5] - Giredestrant also showed a 31% risk reduction in distant recurrence-free interval, with a hazard ratio of 0.69 [2][3] - The efficacy of giredestrant was consistent across all clinically relevant subgroups, and adverse events were manageable and aligned with its known safety profile [2][3] Group 2: Clinical Significance - Giredestrant is the first oral selective estrogen receptor degrader (SERD) to demonstrate superior invasive disease-free survival in the adjuvant setting, marking a significant advancement in endocrine therapy for breast cancer in over 20 years [3][5] - The lidERA study results highlight giredestrant's potential to become a new standard-of-care endocrine therapy for early-stage ER-positive breast cancer, where the chance for cure is highest [2][3] Group 3: Market Context - Approximately 70% of breast cancer cases are ER-positive, with many patients experiencing recurrence after adjuvant endocrine therapy, underscoring the need for more effective and tolerable treatment options [2][8] - Roche's commitment to advancing breast cancer research spans over 30 years, focusing on innovative therapies to address the complexities of various breast cancer subtypes [9][10]